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Reproduction is essential for perpetuation of the species and, hence, is controlled by 
a sophisticated network of regulatory factors of central and peripheral origin that inte-
grate at the hypothalamic–pituitary–gonadal (HPG) axis. Among the central regulators 
of reproduction, kisspeptins, as major stimulatory drivers of gonadotropin-releasing 
hormone (GnRH) neurosecretion, have drawn considerable interest in the last decade. 
However, the dynamic, if not cyclic (in the female), nature of reproductive function and 
the potency of kisspeptins and other stimulatory signals of the HPG axis make tenable 
the existence of counterbalance inhibitory mechanisms, which may keep stimulation at 
check and would allow adaptation of reproductive maturation and function to different 
endogenous and environmental conditions. In this context, discovery of the gonado-
tropin-inhibitory hormone (GnIH) in birds, and its mammalian homolog, RFRP, opened 
up the exciting possibility that this inhibitory signal might operate centrally to suppress, 
directly or indirectly, GnRH/gonadotropin secretion, thus reciprocally cooperating with 
other stimulatory inputs in the dynamic regulation of the reproductive hypothalamic–
pituitary unit. After more than 15  years of active research, the role of GnIH/RFRP in 
the control of the HPG axis has been documented in different species. Yet, important 
aspects of the physiology of this system, especially regarding its relative importance and 
actual roles in the control of key facets of reproductive function, remain controversial. 
In the present work, we aim to provide a critical review of recent developments in this 
area, with special attention to studies in rodent models, using pharmacological tools and 
functional genomics. In doing so, we intend to endow the reader with an updated view 
of what is known (and what is not known) about the physiological role of GnIH/RFRP 
signaling in the control of mammalian reproduction.
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iNTRODUCTiON
Reproductive maturation (including puberty) and function 
are indispensable for perpetuation of the species and, thus, are 
controlled by a sophisticated network of regulatory signals, which 
impact at the so-called hypothalamic–pituitary–gonadal (HPG) 
axis (1). In this system, the group of neurons that synthesize 
and release the decapeptide gonadotropin-releasing hormone 
(GnRH) acts as the common output pathway through which the 
brain, and thereby numerous internal and external cues, controls 
gonadotropins secretion. Accordingly, GnRH neurons are the 
target of complex regulatory actions, conducted by excitatory and 
inhibitory signals, which drive – directly or indirectly – the activ-
ity of this key neuronal population (1). In recent years, numerous 
neuropeptides and transmitters with ability to modulate GnRH 
neurosecretion have been identified. In fact, significant advances 
have been made in the characterization of stimulatory signals of 
GnRH neurons. A paradigmatic example is the identification of 
the puberty/fertility-stimulating neuropeptide, kisspeptin, which 
has profoundly changed our understanding of how the repro-
ductive brain is controlled and how it interplays with other key 
neuroendocrine axes (1, 2). However, less progress has been made 
in the identification of inhibitory signals, which may counterbal-
ance the effects of kisspeptins and other potent elicitors of GnRH/
gonadotropin secretion, thereby playing an equally essential role 
in the precise and dynamic control of the HPG axis.
In this context, identification in 2000 of a novel peptide of 
the RF-amide superfamily, named gonadotropin-inhibitory 
hormone (GnIH) on the basis of its action as Gonadotropin-
Inhibitory Hormone, raised considerable interest (3). For many 
neuroendocrinologists, this turned into excitement when the 
putative ortholog of GnIH, encoding the RF-amide peptides, 
RFRP-1 and RFRP-3, was identified in mammals (4), and the 
capacity of RFRPs to inhibit gonadotropin release was initially 
documented in several mammalian species (4–8). These findings 
paved the way for the characterization of the reproductive (and 
non-reproductive) roles of GnIH peptides in mammals, includ-
ing not only their major effects and mode of action in the control 
of gonadotropin secretion but also their roles on related func-
tions, such as the regulation of food intake (9). In this review, we 
intend to provide a succinct overview of recent data obtained in 
preclinical (mostly rodent) models, using pharmacological tools 
and functional genomics, which help to unveil the physiological 
relevance of GnIH/RFRP signaling in the regulation of the HPG 
axis. In addition, the putative role of this system as connecting 
factor between reproductive function and body energy homeo-
stasis will be briefly discussed.
DiSCOveRY AND MAJOR STRUCTURAL 
FeATUReS OF GniH/RFRP iN MAMMALS
While extensive description of the identification and major 
features of GnIH and their mammalian counterparts, RFRP, can 
be found elsewhere in this Special Issue, in this section we will 
provide, as a means of brief introduction, a succinct recapitula-
tion of key aspects of this class of peptides in mammals, and how 
they were discovered. Of note, RF-amide peptide superfamily in 
mammals comprises a number of central regulators of different 
neuroendocrine axes, including the reproductive (i.e., RFRP and 
kisspeptins) and lactotropic (i.e., PRL-releasing peptides) axes (9, 
10). These peptides share a common RF-amide (Arg-Phe-NH2) 
signature at their carboxyl-terminal region (9). Notably, the first 
isolation of a RF-amide peptide occurred in an invertebrate spe-
cies (11), and led to the discovery of a large series of peptides 
with a similar carboxyl-terminal RF-amide motif in different 
invertebrate and vertebrate species (9, 10). In this context, in 
2000, Tsutsui and colleagues discovered in birds a 12 amino acid 
hypothalamic neuropeptide, with a Ser-Ile-Lys-Pro-Ser-AlaTyr-
Leu-Pro-Leu-Arg-Phe-NH2 sequence, with the distinct capacity 
to inhibit gonadotropin release by cultured quail pituitaries (3). 
This was quite a remarkable finding, as no peptide with similar 
inhibitory activity on gonadotropin secretion had been previously 
identified in vertebrates; hence, this peptide was named GnIH by 
its activity as Gonadotropin-Inhibitory Hormone (3).
The avian GnIH is produced by a gene encoding a precursor 
protein of 173 amino acids that gives rise to three peptides after 
proteolytic cleavage: one is termed GnIH, and the other two are 
named GnIH-1 and GnIH-2 (12, 13). These peptides have a com-
mon carboxyl-terminal LPXRF-amide sequence, where X could 
be L or Q. In the pro-hormone, these sequences are flanked by 
glycine residues on the C-terminus, as well by an amidation signal 
and a basic amino acid on either end, as proteolytic cleavage site 
(14). Using these features as reference, similar sequences have 
been investigated in mammals by searching in gene databases. 
This has allowed the identification of orthologous genes and 
peptides in a number of mammalian species; some of these 
sequences/peptides are shown in a Table 1 (see next page). Notably, 
these analyses allowed identification of two perfectly conserved 
canonical RF-amide peptides, with sequence homology to avian 
GnIH, in rats, mice, and hamsters, namely RFRP-1 and RFRP-3. 
Of note, while RFRP-1 displays higher structural homology with 
avian GnIH than RFRP-3 (4), pharmacological studies strongly 
suggest that RFRP-3 is likely the functional ortholog of GnIH in 
mammals (9, 15).
Indeed, phylogenetic analyses revealed that in different mam-
malian species, the RFRP gene encodes two major structurally 
related peptides: RFRP-1 and RFRP-3 (see Figure  1). These 
peptides have been identified, among others, in the bovine, rat, 
mouse, Syrian and Siberian hamster, monkey, and human species 
(4, 16–21). Additionally, human, macaque, and bovine genes, 
encoding an LPXRF-amide-like peptide, have been identified 
and named RFRP-2 (22). Yet, the homolog precursor cDNA in 
rodents does not encode an equivalent RFRP-2 peptide (10, 23, 
24). Moreover, this peptide does not activate the same receptors 
as RFRP-1 and RFRP-3. Hence, its function as GnIH peptide has 
been questioned.
The biological actions of RFRP-1 and RFRP-3 peptides are 
exerted mainly through the G-protein-coupled receptor, NPFF1R 
(also termed Gpr147). However, RFRP-1 and RFRP-3 can also 
bind with lower affinity to the related receptor, NPFF2R (also 
termed Gpr74) (25). In rats, NPFF1R mRNA is expressed in cen-
tral nervous system, specifically in the hypothalamus, spinal cord, 
amygdala, hippocampus, and substantia nigra, and in peripheral 
TABLe 1 | RFRP peptides identified in mammals, with bird (quail) sequence provided for comparison.
Species Peptide Sequence Reference
Mouse
RFRP-1a VPHSAANLPLRFa (22)
RFRP-3a NMEAGTRSHFPSLPQRFa
Rat
RFRP-1a VPHSAANLPLRFa (22)
RFRP-3 ANMEAGTMSHFPSLPQRFa (16)
Human
RFRP-1 MPHSFANLPLRFa (22)
RFRP-3 VPNLPQRFa
Bovine
RFRP-1 SLTFEEVKDWAPKIKMNKPVVNKMPPSAANLPLRFa (22)
RFRP-3 AMAHLPLRLGKNREDSLSRWVPNLPQRFa (17)
Ovine
RFRP-1a SLTFEEVKDWGPKIKMNTPAVNKMPPSAANLPLRFa (6)
RFRP-3a VPNLPQRFa
Hamster (Siberian)
RFRP-1 SPAPANKVPHSAANLPLRFa
(18)
RFRP-3 TLSRVPSLPQRFa
Hamster (Syrian)
RFRP-1a SPAPANKVPHSAANLPLRFa
(4)RFRP-3a ILSRVPSLPQRFa
Quail
GnIH SIKPSAYLPLRFa (3)
GnIH-RP-1a SLNFEEMKDWGSKNFMKVNTPTVNKVPNSVANLPLRFa (12)
GnIH-RP-2 SSIQSLLNLPQRFa (12)
aDeduced from cDNA sequence.
a, terminal amide group (characteristic of RF-amide motif).
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tissues, such as the pituitary gland, gonads, and eyes (22, 26). 
Furthermore, expression of NPFF1R has been found in the sheep 
pituitary and human gonadotrophs (20, 27, 28). In the hamster, 
NPFF1R expression has been observed in all types of germ cells, 
including sperm, and NPFF2R expression has been detected 
only in more differentiated germinal cells. In the monkey, RFRPs 
receptors are found in testicular Leydig cells, spermatogonia, and 
spermatocytes, as well as in granulosa cells, pre-antral follicles 
and corpora lutea in monkeys and humans (29).
Regarding neuronal populations expressing RFRPs, these 
have been detected mainly in the hypothalamic dorsomedial 
nucleus (DMN) or adjacent areas, and they have been found to 
project to several hypothalamic regions, including the arcuate 
nucleus (ARC), the paraventricular nucleus (PVN), the lateral 
hypothalamus, and the ventromedial nucleus (VMN); all these 
hypothalamic areas are known to play key roles in the control of 
reproduction and energy balance (30).
PHARMACOLOGiCAL ANALYSiS OF GniH/
RFRP eFFeCTS ON THe HPG AXiS iN 
MAMMALS
On the basis of the original work proposing RFRPs as functional 
orthologs of GnIH in mammals (4), in recent years a number of 
studies have aimed to characterize the profiles of (mostly brain) 
expression, as well as the effects and mechanisms of action of 
RFRPs on the HPG axis (mainly on gonadotropin secretion) in 
different mammalian species. For the sake of concision, in this 
section we will focus on the description of the effects RFRPs 
agonists, and especially of RFRP-3 as major functional analog of 
GnIH, on gonadotropin secretion in rodents (mainly) and other 
mammalian species (see Table 2). In addition, effects of RFRP-3 
on related neuroendocrine axes will be also briefly mentioned.
effects of the Administration of RFRP-3 
in Rats
The limited (indirect) data available to date seem to indicate 
that in the rat the GnIH/RFRP system does not play an essential 
role in the regulation of the HPG axis during the developmental 
period that takes place before puberty. This is based on the fact 
that central administration of the agonist, RFRP-3, or antisense 
oligonucleotides (ODNs) against RFRP-3, did not alter the timing 
of puberty in male rats (31). However, RFRP-3 infusion elicited 
a significant decrease in luteinizing hormone (LH) levels, while 
it significantly increased plasma growth hormone (GH) levels 
compared to control rats, suggesting that RFRP-3 may be associ-
ated with peri-pubertal rise in GH secretion (31).
In turn, the GnIH/RFRP system seems to participate in both 
sexes in the maintenance of basal levels of gonadotropins in 
adulthood, exerting an inhibitory effect on the HPG axis, which 
is evidenced by the fact that central administration of RFRP-3 
or its analog, RFRP3–8, induces a rapid decrease in serum LH 
levels (15). Similarly, central injection of RFRP-3 decreased the 
magnitude of the pre-ovulatory surge of LH, independently of 
the prolactin surge (32). The inhibitory effects of RFRP-3 were 
more clearly detected in gonadectomized (GNX) rats, used as 
putative model to ease identification of potential inhibitory 
effects against the prevailing elevated levels of gonadotropins 
caused by GNX. These analyses revealed consistent, albeit mod-
est, inhibitory effects of RFRP-3, but not of RFRP-1, analogs on 
LH and follicle-stimulating hormone (FSH) levels, especially at 
high doses (15). As mentioned earlier, it is intriguing that RFRP-1 
has been shown to display a higher degree of homology with the 
avian GnIH than RFRP-3 (25). Yet, the pharmacological analyses 
in rats strongly suggest that RFRP-3 is actually the functional 
homolog of GnIH in mammals (15). In fact, studies in ovine and 
bovine species have confirmed inhibitory effects of RFRP3–8 on 
A B
FiGURe 1 | in (A), a schematic representation of the cascade of proteolytic processing events necessary to generate a RF-amide mature peptide 
from a precursor protein is shown. Precursor proteins posses N-terminal regions that contain abundant hydrophobic residues, which form the signal peptide 
sequence. On the other hand, the precursor proteins contain a RFGR/K motif, in which R/K is a basic amino acid residue and G is an amide donor; cleavage of this 
area forms the terminal RF-amide signature. In (B), the major structural features and sequences are shown of the two major peptides, RFRP-1 and RFRP-3, 
encoded by the RFRP gene. For RFRP-1, complete sequence homology is detected between hamster, mouse, and rat sequences. For RFRP-3, the mouse 
sequence is presented, which is similar to that of the rat peptide, except for one amino acid residue. Based on Ref. (4, 14) with modifications.
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gonadotropin secretion by cultured pituitary cells (6, 33), with 
higher bio-potency than the larger 17-amino acid RFRP-3 frag-
ment. Moreover, the capacity of central injection of RFRP3–8 
to inhibit LH secretion has been documented not only in GNX 
female rats but also in intact and GNX male rats (15). Inhibitory 
actions of centrally injected RFRP-3 have been also reported on 
FSH secretion in male rats in vivo. Although unambiguous, the 
magnitude of such responses was somewhat modest and detected 
only at the high dose range (≥1 nmol/rat) (15).
In rats, the ability of RFRP to inhibit gonadotropin secretion 
directly at the pituitary gland remains controversial. In fact, some 
studies failed to detect GnIH/RFRP-immunoreactive fibers in 
the median eminence (34). Yet, expression of NPFF1R has been 
detected in the pituitary gland. In line with the latter, our pharma-
cological experiments supported a direct action of GnIH/RFRP 
at the pituitary in rats, as the octapeptide fragment of RFRP-3 
was able to decrease basal and GnRH-stimulated secretion of 
LH by pituitaries from GNX males ex vivo (15). Interestingly, 
comparison of the effective dose-window revealed a dominant 
inhibitory action of RFRP-3 on GnRH-stimulated LH secretion 
at the low physiologic range (10−10  M), which is lost at higher 
concentrations (10−6 M) of the neuropeptide (15).
Additional studies have addressed the predominant (hypo-
thalamic vs. pituitary) site of action of RFRP-3 in the inhibitory 
control of the HPG axis in rats by a combination of in vivo and 
in  vitro approaches. Thus, comparison of the effects on LH 
secretion of central [intra-cerebroventricular (icv)] vs. systemic 
[intravenous (iv)] administration of RFRP-3 in adult ovariecto-
mized (OVX) female rats revealed that, while iv administration 
of RFRP-3 significantly reduced plasma LH levels, icv RFRP-3 
injections failed to alter neither the mean LH levels nor the 
 frequency of the pulsatile LH secretion (8). The latter is at odds 
with other studies addressing the effects of central administration 
of RFRP-3, as described above, and points to a predominant pitui-
tary action of RFRP-3. In the same vein, studies using cultured 
pituitary cells from female rats demonstrated a suppressive effect 
of RFRP-3 on LH secretion, selectively in the presence of GnRH 
(8). Alike, another study showed that RFRP-3 administration 
to OVX rats had no effects on basal secretion, but it inhibited 
GnRH-stimulated LH secretion by about 25% (34).
As final comment to this section, it has been documented 
that in adult males, icv injection of RFRP-3 has been shown to 
significantly increase GH secretion, independently of the time 
of day, while it did not alter plasma levels of thyroid hormone, 
or cortisol (5). In addition, RFRP-3 also has been related to the 
control of neuroendocrine and behavioral stress responses in rats. 
In this context, icv injection of RFRP-3 increased the expression 
of Fos protein in oxytocin neurons in the hypothalamus and 
plasma levels of adrenocorticotropic hormone and oxytocin (35).
effects of the Administration of RFRP-3 in 
Hamsters
In hamsters, the role of the GnIH/RFRP system in the mainte-
nance of basal levels of gonadotropins was initially suggested 
by the observation that in OVX Syrian hamsters, icv injection 
of GnIH induced a rapid reduction of LH levels; similar results 
were obtained after peripheral injections of the peptide (4). By 
contrast, however, a somewhat paradoxical stimulatory role of 
GnIH/RFRP on the gonadotropic axis has been demonstrated in 
male Syrian hamsters. Thus, acute central injection of RFRP-3 has 
been shown to induce c-Fos expression in GnRH neurons, and 
to increase LH, FSH, and testosterone secretion in male (but not 
female) Syrian hamsters (36). This result suggests that the effects 
TABLe 2 | Summary of the reported effects of the administration of 
RFRP-3 in mammals.
Species RFRP-3 Reference
Rat
Anti-RFRP ODN treatment in peri-pubertal rats caused 
a significant increase in plasma LH, but not FSH, 
levels
(31)
RFRP-3 administration to peri-pubertal rats caused a 
significant decrease in plasma LH levels and significant 
increase in plasma GH levels
Central (icv) administration of RFRP-3 significantly 
reduced plasma LH levels and increased circulating 
GH, but did not alter plasma levels of FSH, thyroid 
hormone or cortisol
(5)
RFRP-3, but not of RFRP-1, analogs had inhibitory 
effects on LH and/or FSH levels
(15)
RFRP-3 suppressed the pre-ovulatory GnRH/LH 
surge independently of the prolactin surge
(32)
In adult OVX rats, systemic (iv) administration of 
RFRP-3 lowered plasma LH levels, while icv injections 
RFRP-3 failed to alter neither the mean levels of LH 
nor the frequency of the pulsatile LH secretion
(5)
In cultured pituitary cells, the suppressive effect of 
RFRP-3 on LH secretion was not clearly detectable in 
the absence of GnRH, but in the presence of GnRH, 
RFRP-3 significantly suppressed LH secretion in vitro
RFRP-3 administration to OVX rats had no detectable 
effects on basal LH secretion, but inhibited GnRH-
stimulated LH secretion
(34)
Icv injection of RFRPs increased the plasma levels of 
ACTH and oxytocin
(35)
In adult males, icv injection of RFRP-3 significantly 
reduced plasma levels of LH and increased GH 
independently of the time of day; however, it did not 
alter plasma FSH, thyroid hormone, or cortisol levels
(8)
Hamster
In female (OVX) Syrian hamsters, GnIH administration 
(central or peripheral) rapidly inhibits LH secretion
(7)
In male Syrian hamsters, acute central injection of 
RFRP-3 induces c-Fos expression in GnRH neurons 
and increases LH, FSH, and testosterone secretion
(36)
Central (icv) administration of RFRP-1 or RFRP-3 to 
male Siberian hamsters decreased LH and FSH levels 
in long-day conditions, but stimulated LH secretion in 
short-day conditions
(18)
Mouse
In electrophysiological studies, an inhibitory effect of 
RFRP-3 on the excitability of GnRH neurons has been 
shown in male and female mice
(37)
RFRP-3 has been shown to lower plasma LH levels 
in vivo (after icv injection) and LH secretion in vitro 
(pituitary explants)
(38)
RFRP-3 has been suggested to inhibit testicular 
steroidogenesis and spermatogenesis, either indirectly 
through GnRH or by directly influencing germ cell 
proliferation, survival, and apoptosis
(39)
GnIH inhibited follicular development and 
steroidogenesis in the mouse ovary
(40)
Sheep
Peripheral administration of GnIH decreased the 
amplitude of LH pulses, while GnIH decreased the 
secretion of LH and FSH in vitro
(6)
Human RFRP-3 reduced FSH, LH, and forskolin-stimulated 
progesterone secretion by human granulosa cells
(41)
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of RFRP-3 administration on the gonadotrophic axis may be sex 
dependent, at least in the Syrian hamster (36). Of note, icv admin-
istration of RFRP-1 or RFRP-3 to male Siberian hamsters induced 
a significant decrease in LH and FSH levels under long-day 
photoperiodic conditions, while, in sharp contrast, both peptides 
stimulated LH secretion after administration to hamsters under 
a short-day regimen (18). This would suggest that, in addition to 
sex, external light cues and photoperiod would play a dominant 
role in defining inhibitory vs. stimulatory responses to GnIH/
RFRP in hamsters.
effects of the Administration of RFRP-3 
in Mice
Electrophysiological studies have shown an inhibitory effect of 
RFRP-3 on the excitability of GnRH neurons in male and female 
mice (37). The effects were found to be of rapid onset, dose 
dependent, and repeatable, suggesting a typical neurotransmitter 
mode of action of RFRP-3 on GnRH neurons. However, it is noted 
that RFRP-3 displayed mixed actions on the firing rate of GnRH 
neurons, with >40% being inhibited but 12% being activated by 
RFRP-3 (37). In any event, these observations as a whole support 
a role for RFRP-3 in the modulation of GnRH neuron activity, as 
major mechanisms for its action in the regulation of gonadotro-
pin secretion (37). To date, the effects of RFRP-3 on gonadotropin 
secretion in vivo have been scarcely studied in the mouse. In fact, 
to our knowledge, only one study, coming from our group, has 
shown an inhibitory effect of RFRP-3 on LH secretion in  vivo 
in the mouse, using a standard OVX model. Thus, central (icv) 
administration of 5 nmol RFRP-3 to OVX mice evoked a 25% 
suppression of LH levels (38). Likewise, pituitary explants from 
male mice, exposed to RFRP-3 in vitro, displayed a suppression of 
LH secretion (38). In addition, a recent study showed that RFRP-3 
treatment induces significant changes in body mass, circulating 
steroid level and testicular activity in mice (39). Notably, RFRP-3 
treatment also caused dose-dependent histological changes in 
spermatogenesis, such as a decline in germ cell proliferation and 
survival markers and an increase in apoptotic markers in testis. 
This study also suggested that the inhibitory effect of RFRP-3 
in the testis might be mediated through local production of 
GnRH. Thus, RFRP-3 could inhibit testicular steroidogenesis and 
spermatogenesis either indirectly through GnRH or by directly 
influencing germ cell proliferation, survival, and apoptosis (39). 
Additionally, GnIH has been shown to inhibit follicular develop-
ment and steroidogenesis in the mouse ovary (40).
effects of the Administration of RFRP-3 in 
Ovine and Primate Species
While, for sake of concision, we have focused our review in rodent 
studies, it is interesting to note that in vivo and in vitro studies 
have demonstrated an inhibitory effect of GnIH on reproduction 
in ewes, where the peripheral administration of GnIH decreased 
the amplitude of LH pulses, while in vitro GnIH decreased the 
secretion of LH and FSH (6).
In addition, it is notable that the RFRP/NPFF1R system has 
been shown to be expressed in the gonads of primates; thus, 
indirectly suggesting that GnIH/RFRP might exert a direct role 
in the control of gonadal physiology. In this sense, treatment of 
human granulosa-lutein cells with RFRP-3 reduced FSH, LH, 
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and forskolin-stimulated progesterone secretion (41). To our 
knowledge, the effects of GnIH/RFRP on the secretory profiles 
of gonadotropins in primates (including humans) have not been 
reported to date.
ANALYSiS OF GniH/RFRP ROLeS ON THe 
HPG AXiS USiNG ANTAGONiSTS: 
STUDieS wiTH RF9
As summarized in previous sections, the available pharmacologi-
cal data strongly suggest that RFRPs are involved in the regulation 
of the HPG axis in mammals, by delivering (predominantly) an 
inhibitory signal to the central elements of the gonadotropic axis. 
However, as also reviewed above, the integral analysis of the phar-
macological data surfaces some inconsistencies and differences, 
which have fueled the debate on the actual physiological relevance, 
relative importance (vs. other regulatory systems) and major sites 
of action of this neuropeptide system in the control of gonadotro-
pin secretion in mammals (25). To some extent, this is due to the 
fact that the study of the physiological actions of GnIH/RFRP has 
been mostly based on the use of indirect experimental approaches, 
involving expression analyses or the testing of pharmacological 
doses of exogenous agonists. By contrast, direct assessment of the 
roles of endogenous RFRPs in mammals has been hampered by 
the lack of potent and selective antagonists of RFRP signaling.
In this context, in 2006, the compound RF9 was reported as a 
potent and selective antagonist of NPFF receptors, with binding 
affinity and antagonistic activity at the level of both NPFF1R and 
NPFF2R (42). Notably, initial pharmacological characterization 
of this compound focused on the analyses of NPFF-mediated 
events; it was shown that RF9 effectively blocks the effects of NPFF 
on heart rate and blood pressure, and it was capable to prevent 
opioid-induced hyperalgesia and tolerance in rats, phenomena 
that are presumably mediated via NPFF2R (42). However, it 
was not until 2010 when the first study addressing the impact 
of RF9-mediated RFRPR blockade, as putative receptor pathway 
for mediating GnIH/RFRP actions, on gonadotropin secretion in 
rodents was published by our group (43).
The effects of RF9 on gonadotropin secretion were initially 
explored in cycling female rats. Intracerebral injection of RF9 
evoked robust LH secretory responses in cycling rats at the two 
stages of the cycle tested, estrus and diestrus-1 (D-1), with peak 
values at 30 min and persistently elevated LH levels during the 
120-min period after RF9 injection. The testing of a wide range 
of doses of RF9 (10 and 100  pmol, and 1, 5, and 20  nmol; icv 
injection) demonstrated consistent stimulation for doses of RF9 
from 5 nmol onwards (43). Similar dose–response curves were 
generated in adult male rats after icv injection of different doses of 
RF9. Consistent stimulation of LH secretion was detected in male 
rats from doses of 1 nmol/icv onward. In addition, RF9 elicited 
significant elevations of circulating FSH levels in cycling females 
at estrus, but not at D-1; moreover, only the dose of 20 nmol RF9 
icv was capable of eliciting unambiguous FSH responses in male 
rats (43).
In mice, RF9 elicited robust LH secretory peaks at 15 min after 
its icv injection, which represented >20-fold increase over basal 
levels; LH responses to RF9 in mice were similar in amplitude 
between males and females (43, 44). However, central injection 
of RF9 failed to evoke significant FSH responses in female mice, 
whereas it elicited a modest 35% increase in serum FSH levels 
in adult males. In addition, RF9 blocked the inhibitory effects of 
NPFF on GnRH neuron pacemaker activity (45).
The potential interplay of GnIH/RFRP with sex steroid lev-
els and the functional status of the HPG axis in the control of 
gonadotropin secretion have been pharmacologically explored 
also in various species using RF9. Thus, iv administration of RF9 
increased plasma LH levels in orchidectomized (ORX) male rats, 
but this stimulatory effect was completely blunted after blockade 
of GnRH actions (46). On the other hand, the stimulatory effects 
of RF9 on gonadotropin secretion were detected despite the 
prevailing suppression of gonadotropin levels by testosterone 
or estradiol. In fact, central administration of RF9-induced 
extraordinarily potent in vivo LH responses in ORX mice receiv-
ing a fixed dose of testosterone, while RF9 reversed the inhibitory 
effects of testosterone on GnRH release frequency from brain 
slices in  vitro (47). In turn, blockade of estrogen receptor-α 
partially attenuated gonadotropin responses to RF9 in rats (43). 
In other species, like the ewe, icv injection of RF9 during anes-
trus or the breeding season caused a clear elevation of plasma 
LH levels, with a more pronounced effect during the anestrous 
season (48). Furthermore, peripheral administration of RF9 as 
a bolus or as a constant iv infusion to anestrous ewes induced 
a sustained increase in plasma LH levels (48). A summary of 
the reported effects of RF9 in different mammalian species is 
presented in Table 3.
Despite the fact that the above pharmacological evidence is 
suggestive of a tonic suppression of gonadotropin tone by GnIH/
RFRP, as blockade of this signaling pathway by RF9 causes a 
robust increase in LH (and to a lesser extent, FSH) levels, recent 
doubts have been raised about the interpretation of hormonal 
studies using this GnIH/RFRP antagonist. A call of caution 
for interpretation of the gonadotropic effects of RF9 was made 
already in initial publications, given the capacity of RF9 to block 
both NPFF1R and NPFF2R. Yet, the function of RF9, as putative 
selective antagonist of NPFFRs, together with the conspicuous 
lack of other NPFF1R antagonist, made RF9 an appealing candi-
date for neuroendocrine studies.
These doubts have recently substantiated in the context of 
analyses of the potential interplay of GnIH/RFRP and kisspeptins 
using RF9 as pharmacological probe. Initial studies demonstrated 
that co-injection of RF9 and kisspeptin-10 (Kp-10) resulted in 
elevated LH levels that were similar to those observed after icv 
administration of RF9 alone, except for a longer duration of those 
evoked by the combined administration of RF9 and Kp-10 (43). In 
fact, co-administration of RF9 and Kp-10 elicited FSH secretory 
responses that were not statistically different from those of RF9. 
To further explore the putative interplay between GnIH/RFRP 
and kisspeptins, the effects of RF9 on gonadotropin secretion were 
evaluated in Gpr54 KO mice, which are genetically engineered to 
lack kisspeptin signaling. While persistent LH responses to RF9 
were observed in the absence of functional kisspeptin receptors, 
the absolute magnitude of such responses was severely blunted, 
as it was about one-tenth of that observed in WT animals (44). 
TABLe 3 | Summary of the reported effects of RF9 administration on the 
HPG axis in mammals.
Species RF9 Reference
Rat
Intravenous treatment with RF9 increased circulating 
LH levels in ORX male rats, but failed to evoke LH 
secretion after blockade of GnRH actions
(42)
Central administration of RF9 evoked a dose-
dependent increase of LH and FSH levels in adult 
male and female rats
(43)
Administration of RF9 further augmented the 
gonadotropin-releasing effects of kisspeptin 
(duration of responses), and its stimulatory effects 
were detected despite prevailing suppression of 
gonadotropin secretion by testosterone or estradiol
In males, systemic administration of RF9 modestly 
stimulated LH secretion in vivo and had no direct 
effects in terms of gonadotropin secretion by the 
pituitary in vitro
Co-administration of the kisspeptin antagonist, p234, 
blunted LH responses to RF9 (44)
Mouse
Central (icv) injection of RF9 elicited with robust LH 
secretory responses in mice
(43)
LH responses to RF9 were severely blunted in Gpr54 
KO mice, with absolute magnitudes that were only 
one-tenth of WT mice
(44)
Central (icv) administration of RF9 induced potent 
LH responses in ORX mice getting a fixed dose of 
testosterone, but these were absent in ORX Gpr54 
KO mice with similar testosterone replacement
RF9 blocked the inhibitory effects of NPFF on GnRH 
neuron pacemaker activity and reversed the inhibitory 
effects of testosterone on GnRH secretory frequency
(45)
Central (icv) administration of RF9 evoked very potent 
LH secretory responses in mice genetically devoid of 
NPFF1R
(51)
Sheep
Central (icv) and peripheral administration of 
RF9 induced significant increases in LH plasma 
concentrations in the ewe, especially in the anestrous 
season
(48)
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Moreover, LH responses to RF9 were totally suppressed in ORX 
Gpr54 KO mice receiving testosterone implants (44). Altogether, 
these data strongly suggest that a preserved kisspeptin signaling is 
essential for the manifestation of the potent gonadotropin-releas-
ing effects of RF9. Along with this view, it was recently demon-
strated that the excitatory effects of RF9 on GnRH neuronal firing 
do not occur in Gpr54 KO mice (49). Furthermore, it has been 
very recently shown that pharmacological blockade of kisspeptin 
receptors, by the use of the antagonist p234, blunted RF9-induced 
LH secretion in female rats (50). Admittedly, however, these 
observations do not necessarily exclude the possibility that the 
lowering of inhibitory actions of GnIH/RFRP, eventually caused 
by RF9, might need preserved kisspeptin inputs to translate into 
detectable LH secretory responses.
Yet, very recent studies, combining in vitro and in vivo analy-
ses, further support a primary action of RF9 directly via Gpr54 
(51). Thus, analyses using CHO cells stably expressing Gpr54 
have demonstrated the capacity of RF9 to bind the kisspeptin 
receptor and to activate its canonical intracellular signaling 
cascade, including increases in intracellular calcium and inositol 
phosphate, as well as ERK phosphorylation (51). In good agree-
ment, our studies in  vivo have demonstrated that RF9 evokes 
very potent LH-releasing responses in a mouse line genetically 
devoid of NPFF1R, the Npff1r−/− mouse (see Analysis of the 
GnIH/RFRP Roles in the HPG Axis Using Functional Genomics: 
the Npff1r−/− Mouse). Moreover, while LH responses to RF9 were 
severely blunted in Gpr54 null mice, the stimulatory effects of 
RF9 were rescued by selective re-expression of Gpr54 in GnRH 
neurons (51). Altogether, these observations strongly suggest that 
at least a substantial component of the secretory effects of RF9 on 
gonadotropin secretion stems from its capacity to activate Gpr54, 
rather than its blocking effects on NPFF1R.
As final note to this section, a very recent study has reported 
the identification and pharmacological characterization of a 
novel NPFFR antagonist, termed GJ14, with improved specific-
ity in terms of receptor interaction and blockade (52). Notably, 
this study has documented that infusion of GJ14 effectively 
blocked the anxiogenic and corticosterone-stimulatory effects 
of RFRP-3 in mice (52). To our knowledge, the impact of this 
novel antagonist on the function of the HPG axis has not been 
reported so far. Similarly, additional in vivo studies are warranted 
to further evaluate the specificity of GJ14 and its eventual (lack 
of) interaction with other central regulators of GnRH/gonado-
tropin secretion.
ANALYSiS OF THe GniH/RFRP ROLeS iN 
THe HPG AXiS USiNG FUNCTiONAL 
GeNOMiCS: THE Npff1r−/− MOUSE
As summarized in previous sections, compelling pharmacologi-
cal evidence suggests that GnIH/RFRP plays a role in the inhibi-
tory control of the HPG axis in mammals. However, the actual 
physiological relevance of this system remained incompletely 
defined, mainly because of conflictive results concerning the 
nature, magnitude, and major sites of action of RFRP-3 in the 
control of gonadotropin secretion. To some extent, these uncer-
tainties were due to the lack of appropriate experimental models 
and investigative tools to address the physiological functions of 
GnIH/RFRP in vivo. A major advancement in this area, however, 
took place recently, when the reproductive characterization of 
the first mouse line with genetic inactivation of NPFF1R was 
published by our group (38). This piece of work, which analyzed 
the impact of congenital ablation of NPFF1R on fecundity, litter 
size, puberty, adult gonadotropic function, gonadal feedback, and 
NPFF/Kiss1 interactions, is considered relevant to ascertain the 
relative importance of this system in the control of reproductive 
function in mammals (38).
As expected, mice deficient for NPFF1R did not respond to 
icv administration of RFRP-3 (38), in contrast to the preserved 
inhibitory responses observed in WT mice, where RFRP-3 sup-
pressed LH secretion, in keeping with previous literature (15). In 
addition, while pituitary explants from WT male mice responded 
to RFRP-3 with a significant suppression of LH secretion in vitro, 
this inhibitory response was not detected in the pituitaries from 
Npff1r−/− animals (38). The latter data evidence that RFRP-3 can 
partially act directly at the pituitary level to suppress LH secretion 
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in mice. Interestingly, whereas pituitaries from both WT and 
NPFF1R KO mice responded to GnRH with robust LH secretory 
responses in vitro, the magnitude of such responses was (mod-
estly) higher in NPFF1R KO mice, suggesting that null animals 
are devoid of inhibitory mechanisms that restrain stimulated LH 
secretion (38).
In keeping with the presumable role of GnIH/RFRP as 
inhibitor of gonadotropin secretion, NPFF1R-deficient male and 
female mice had preserved fertility. In fact, the mean size of litters 
from NPFF1R KO pairs was significantly higher than that of WT 
breeders (38). Pubertal analyses of null animals evidenced that 
KO males, but not females, displayed constitutively elevated LH 
levels before and during puberty, whereas FSH levels were simi-
lar between genotypes during the pubertal transition. Pubertal 
progression was not apparently altered by the congenital lack of 
NPFF1R, as evidenced by similar mean ages of occurrence of 
external signs of puberty: balano-preputial separation in males 
and vaginal opening in females. In addition, testicular and ovar-
ian maturation, as well as ovulatory dynamics, were similar in 
WT and KO mice, and NPFF1R KO female mice showed pre-
served estrous cyclicity and pre-ovulatory LH surges of similar 
magnitude as in WT mice (38).
In addition, the functionality of the gonadotropic axis in 
the absence of GnIH/RFRP signaling was further explored by 
studying LH responses to three major regulators of gonadotro-
pin secretion, namely GnRH, Kp-10, and senktide, in NPFF1R 
null male mice. Of note, senktide is an agonist of neurokinin B 
(NKB), which has been shown to be co-expressed in a subset of 
Kiss1 neurons, located in the ARC, where NKB would operate as 
activator of kisspeptin release onto GnRH neurons (2). Systemic 
[intra-peritoneal (ip)] injection of GnRH elicited enhanced LH 
responses in KO mice, in good agreement with the responses 
observed in the incubations of pituitary explants. In turn, central 
administration of Kp-10 induced an increase in LH levels similar 
in both genotypes, while activation of NKB signaling induced 
lower LH responses in NPFF1R KO mice compared to WT ani-
mals. Such differences in the patterns of response to these factors 
(GnRH, Kp-10, NKB) are probably due to the differences in their 
sites of action as GnRH acts at the pituitary whereas NKB operates 
mainly at the level of ARC Kiss1 neurons, and how these sites are 
differentially affected by the lack of GnIH/RFRP actions (38). In 
addition, the analysis by in situ hybridization of the levels of Kiss1 
mRNA in the two major hypothalamic areas of expression (the 
ARC and the anteroventral periventricular nucleus, i.e., AVPV) 
in NPFF1R KO mice showed that the overall expression level of 
Kiss1 and the number of Kiss1 neurons were significantly higher 
in the ARC, but not in the AVPV, of NPFF1R KO animals, sug-
gesting that RFRP signaling carries out a tonic repression of Kiss1 
gene expression at this site (38). Of note, it has been reported 
that approximately one-forth of ARC Kiss1 neurons actually co-
express NPFF1R, while only a very small fraction of AVPV Kiss1 
neurons expressed NPFF1R or NPFF2R (53).
The putative interplay between GnIH/RFRP and kisspeptin 
was further explored by the generation of a double KO mouse, 
where both inhibitory (NPFF1R) and stimulatory (Gpr54) recep-
tors were genetically ablated. With this approach, we aimed to 
explore whether elimination of the inhibitory signal driven by 
RFRP might (at least partially) compensate the profound hypo-
gonadotropic hypogonadism induced by the lack of kisspeptin 
signaling. However, analysis of this double NPFF1R/Gpr54 KO 
mouse line revealed that the absence of RFRP signaling was not 
sufficient to rescue nor did it improve the severe gonadal failure 
of Gpr54 KO mice, as this double mutant line showed remarkable 
phenotypic and hormonal similarities with single Gpr54 null mice 
(38). These findings strongly suggest that, despite some interplay 
between kisspeptin and GnIH/RFRP signaling, kisspeptin func-
tion clearly predominates in the central control of the HPG axis.
Finally, the roles of GnIH/RFRP in the negative feedback con-
trol of gonadotropin secretion were also explored using Npff1r−/− 
mice. To this end, protocols of GNX were applied to male and 
female WT and KO mice. Removal of sex steroids revealed a 
delay in LH responses to the removal of gonadal steroids in the 
mutant mice of both sexes. However, in longer term, the absence 
of the NPFF1R caused sexually dimorphic alterations in post-
GNX responses: while in female mutant mice, circulating levels 
of LH were significantly higher than those in WT from 7-days 
post OVX onward; in male mice, LH responses were normalized 
7-days after ORX, and remained similar to those of WT from that 
period onward. These data suggest that in females, but apparently 
not in males, the GnIH/RFRP system operates as (moderate) 
brake to modulate the increase in circulating LH levels following 
the removal of negative feedback signals from the gonads (38).
In sum, functional genomic approaches have allowed to 
characterize the neuroendocrine (gonadotropic) impact of the 
constitutive lack of GnIH/RFRP signaling, thereby providing 
a direct assessment of the relative importance of this system in 
the control of the HPG axis. These analyses revealed alterations, 
such as increased litter size, increased gonadotropin levels at 
certain developmental stages, increased Kiss1 expression in the 
ARC, and altered post-OXV responses in the Npff1r−/− mouse, 
which are in general compatible with an inhibitory role of GnIH/
RFRP signaling in the control of reproductive function. It must 
be stressed, however, that most of these changes were moderate in 
nature and subordinated to preserved kisspeptin signaling (38). 
Yet, the possibility exists that developmental compensation (e.g., 
via NPFF2R, whose expression is preserved in this KO model) 
might have masked to some extent the phenotypic impact of the 
lack of NPFF1R signaling.
GniH/RFRP AS PUTATive LiNK FOR THe 
iNTeGRAL CONTROL OF 
RePRODUCTiON AND MeTABOLiSM
The existence of a close relationship between energy balance and 
reproduction is well established and there is compelling evidence 
that forms of metabolic stress, such as conditions of negative 
energy balance, result in the inhibition of reproductive function. 
Similarly, alterations of the HPG axis may be linked to metabolic 
perturbations (54). Despite this evidence, the basic mechanism by 
which this reciprocal control occurs remains partially unknown. 
This has prompted the analysis of the metabolic effects of different 
factors primarily involved in the control of reproductive function 
and vice versa.
FiGURe 2 | Schematic diagram of the putative interplay of neurons 
expressing GniH/RFRP with key elements of the HPG axis, including 
pituitary gonadotrophs and hypothalamic GnRH and Kiss1 neurons.  
A prominent population of GnIH neurons has been identified in the 
paraventricular nucleus (PVN). On the basis of neuroanatomical studies (e.g., 
on neuronal projections) and expression analyses (e.g., of receptors), different 
sites of action of the GnIH/RFRP system have been proposed, as depicted in 
the scheme. Admittedly, however, the relative importance of the different sites 
of action might vary between mammalian species. Alike, direct gonadal 
effects of GnIH/RFRP (not depicted in this scheme) have been proposed also 
on the basis of experimental data.
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In this context, evidence has been recently presented support-
ing a potential role of GnIH/RFRP as a potential link between 
reproductive and metabolic homeostasis. Thus, central (icv) 
administration of RFRP-3 has been shown to stimulate food 
intake in adult male rats (55). In turn, it has been reported that 
RF9 decreased food intake without affecting body weight in 
female rats (50); yet, the possibility exists that RF9 might evoke 
such anorectic responses acting via Gpr54, as kisspeptin has been 
shown to suppress feeding as well (56). However, microinjections 
of RFRP-3 in the central part of amygdala resulted in a significant 
decrease of food intake in rats; an effect that was eliminated after 
RF9 pre-treatment (57). All in all, the pharmacological data avail-
able suggest a predominant orexigenic role of RFRP-3, supported 
also by data obtained in sheep (55); yet, at some brain areas, 
GnIH/RFRP signaling might evoke food-suppressing responses. 
Assuming that orexigenic factors are activated in conditions of 
negative energy balance (as to promote food seeking), it is tenable 
that GnIH/RFRP might contribute to the suppression of gonado-
tropic function observed in condition of energy deficit (55).
This possibility has been recently addressed using the Npff1r−/− 
mouse and protocols of short-term fasting as form of metabolic 
stress (38). While in WT animals, food deprivation caused a 
significant lowering of LH levels already at 12-h after beginning 
of fasting, such a rapid drop of LH was not detected in NPFF1R 
KO mice subjected to a similar fasting regimen, despite the lower-
ing of body weight was proportionally higher than that in WT 
animals (38). This observation suggests that activation of GnIH/
RFRP signaling might contribute to the suppression of gonado-
tropin levels observed in conditions of negative energy balance. 
Indeed, previous studies have shown an increase in the activity 
of RFRP-positive neurons during periods of undernutrition in 
hamsters (58). Interestingly, NPFF1R null mice displayed also 
partially preserved gonadotropic function in response to other 
forms of metabolic stress linked to reproductive alterations, such 
as diet-induced obesity. Thus, feeding with high-fat diet (HFD) 
for 9 weeks evoked >40% weight gain in WT mice, which was 
associated with a significant decrease in circulating LH levels. By 
contrast, in NPFF1R KO mice, HFD feeding did not induce signifi-
cant changes in circulating LH levels, in spite of a similar weight 
gain as in WT mice (38). Overall, these observations suggest that 
the mechanisms by which extreme metabolic conditions inhibit 
gonadotropin secretion probably involve changes in signaling by 
GnIH/RFRP, such as an increase of the inhibitory tone by RFRP.
CONCLUDiNG ReMARKS
Identification of GnIH in birds, and of its mammalian orthologs, 
RFRPs, has opened up new avenues for our understanding of the 
central mechanisms for the control of the HPG axis. As illustrated 
in Figure 2, expression and functional studies strongly suggest 
that GnIH/RFRP signaling may play a role in the dynamic control 
of key elements of the HPG axis, including prominently pituitary 
gonadotrophs and hypothalamic GnRH and (eventually) Kiss1 
neurons. However, while the pharmacological data gathered to 
date point to a predominant inhibitory effect of GnIH/RFRP on 
gonadotropin secretion across mammals, some controversy per-
sists regarding the nature (stimulatory in some instances), major 
sites of action (hypothalamic vs. pituitary) and relative impor-
tance (as compared with other neuropeptides) of the GnIH/RFRP 
system in the control of the gonadotropic axis in different species. 
Alike, the interplay of RFRP with other central transmitters with 
key roles in the reproductive brain, such as kisspeptins, has been 
suggested, but further investigation is needed to fully expose the 
interactive partners and interdependence of GnIH/RFRP with 
key central and peripheral regulators of the HPG axis. In this 
review, we intended to provide a succinct view of the state-of-
the-art of the field, by summarizing recent pharmacological data 
and studies using genetically modified models. By doing so, we 
aimed to define what we know, and we do not know, about the 
physiology of GnIH in mammals, as a means to set the scene 
for further research in this exciting and rapidly evolving area of 
Neuroendocrinology.
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